With content supported by more than 86,000 total references and reviewed by over 500 professionals, AHFS DI(R) helps you protect your patients and your business. The only print compendium designated by the U.S. Congress, AHFS DI(R) 2016 is also the only reference published by a professional and scientific society--ensuring it is the most authoritative and best-selling reference trusted by pharmacists for 58 years.

AHFSI DI(R) contains the most trustworthy drug information available--all in one place. It is the most comprehensive evidence-based source of drug information complete with therapeutic guidelines and off-label uses.

Updates for this edition include:

• Expanded and revised content throughout, featuring critical new monograph updates every year
• Important updated monographs and references related to revised therapeutic guidelines, including revised recommendations for the treatment of HIV infections in adult and pediatric patients
• Newly published information on breakthrough oncology drugs approved as part of the FDA's accelerated approval program
• Dedicated coverage to orphan products
• Interactions, adverse reactions, cautions, and more
• Therapeutic recommendations supported by evidence from primary research
• Preparations, chemistry, and stability
• Pharmacology and pharmacokinetics
• Prescription, OTC, ophthalmic and dermatologic drugs
• Extensive off-label uses and dosing options
• Vaccines and other immunizing agents